IMPACT Therapeutics, Inc. has filed for a Global Offering of 41.98 million H shares on the Stock Exchange of Hong Kong, setting an indicative price range of HK$19.75 to HK$21.75 per share. At the top end, the base deal could raise about HK$913 million before any exercise of the over-allotment option and before fees and expenses.

The offering comprises: • Hong Kong Public Offering: 4.20 million H shares (10% of the base deal, subject to reallocation). • International Offering: 37.78 million H shares (90% of the base deal, subject to reallocation and the over-allotment option).

Reallocation provisions allow up to 2.10 million shares to be shifted to the Hong Kong tranche, bringing that tranche to a maximum 6.30 million shares (15% of the deal) if demand warrants and the final price is fixed at the bottom of the range.

An over-allotment option grants underwriters the right to purchase up to 6.30 million additional shares—15% of the initial offering size—within 30 days of the close of the Hong Kong Public Offering. Full exercise would expand the float by roughly 2.2%.

Key dates: • Offer period: 9:00 a.m. on 5 May 2026 to 12:00 noon on 8 May 2026 (Hong Kong time). • Pricing deadline: by 12:00 noon on 11 May 2026. • Allocation results and final price announcement: no later than 11:00 p.m. on 12 May 2026. • Expected first day of trading: 9:00 a.m. on 13 May 2026 under stock code 7630, in board lots of 200 shares.

Goldman Sachs (Asia) L.L.C. is acting as stabilizing manager and may conduct price-support transactions for up to 30 days after listing, ending on 7 June 2026.

The H shares carry a nominal value of RMB1.00 each. Applications for the Hong Kong Public Offering are fully electronic, via the White Form eIPO platform or the HKSCC EIPO channel, with a minimum subscription of 200 shares.